Does Keytruda Have Patient Assistance Programs?
Merck, the maker of Keytruda (pembrolizumab), offers the KEYTRUDA Patient Support Program. It provides free medication to eligible uninsured or underinsured U.S. patients with a valid prescription who meet financial need criteria, such as household income at or below 700% of the federal poverty level (around $103,000 for a single person in 2024).[1] Apply through a doctor or by calling 1-855-4KEYTRUDA.
Who Qualifies and How to Apply?
Eligibility requires U.S. residency, no government insurance (like Medicare), and proof of income/financial hardship. Approved patients get up to 12 months of treatment, renewable annually. Doctors submit via the program's portal; patients can check status online or by phone. Processing takes about 10 days.[1]
What If You're on Medicare or Insurance?
Medicare patients can't get free drug through this program but may qualify for the Merck Access Program, offering co-pay support up to $25,000 per year for commercial insurance or Part D plans (excludes government plans). No income limits here, but you need commercial coverage.[1] Uninsured patients without the main program eligibility might access Merck's bridge program for short-term supply while applying elsewhere.
Other Ways to Lower Keytruda Costs
- Manufacturer Co-Pay Cards: Reduces out-of-pocket to $0 for eligible commercially insured patients (annual cap $25,000).[1]
- Independent Foundations: PAN Foundation or Patient Access Network covers copays/gaps for cancer patients (income-based, up to $15,000/year).[2]
- Patient Advocate Foundation: Co-Pay Relief (CPRC) for immunotherapy drugs like Keytruda (eligibility under 500% FPL).[3]
- Drug Discount Cards: GoodRx or SingleCare can drop cash prices to $8,000-$10,000 per dose (list price ~$11,500), though less relevant for infused drugs.[4]
Why Is Keytruda So Expensive and When Might Costs Drop?
Keytruda's U.S. list price is about $11,500 per infusion (every 3-6 weeks), driven by its broad oncology approvals (over 30 indications). Patents protect it until at least 2028, with some expiring later; no biosimilars yet approved. Challenges from Amgen and others are ongoing, potentially opening generics by 2030s.[5] Exclusivity ends in 2028 for some uses.[1][5]
Sources
[1]: Merck Keytruda Support
[2]: PAN Foundation
[3]: Patient Advocate Foundation
[4]: GoodRx Keytruda
[5]: DrugPatentWatch Keytruda